- Home
- COKE vs MRNA Comparison
COKE vs MRNA Comparison
Compare COKE & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COKE | MRNA |
|---|---|---|
| Founded | 1902 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 9.3B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | COKE | MRNA |
|---|---|---|
| Price | $165.94 | $29.92 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $33.25 |
| AVG Volume (30 Days) | 453.3K | ★ 9.8M |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.60% | N/A |
| EPS Growth | ★ 22.14 | N/A |
| EPS | ★ 7.03 | N/A |
| Revenue | ★ $7,070,308,000.00 | $2,232,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.77 |
| P/E Ratio | $22.90 | ★ N/A |
| Revenue Growth | ★ 4.22 | N/A |
| 52 Week Low | $105.21 | $22.28 |
| 52 Week High | $168.21 | $48.92 |
Technical Indicators
Market Signals| Indicator | COKE | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 67.36 | 65.99 |
| Support Level | $159.13 | $26.90 |
| Resistance Level | $168.21 | $26.00 |
| Average True Range (ATR) | 3.73 | 1.14 |
| MACD | -1.32 | 0.59 |
| Stochastic Oscillator | 70.70 | 85.99 |
Price Performance
Historical ComparisonAbout COKE Coca-Cola Consolidated Inc.
Coca-Cola Consolidated Inc distributes, markets and manufactures nonalcoholic beverages. It offer a range of nonalcoholic beverage products and flavors, including both sparkling and still beverages. Sparkling beverages are carbonated beverages and the Company's principal sparkling beverage is Coca Cola. Still beverages include energy products and noncarbonated beverages such as bottled water, ready-to-drink tea, ready-to-drink coffee, enhanced water, juices and sports drinks. The Company has three operating segments: Nonalcoholic Beverages, All Other and Eliminations. key revenue is generated from Nonalcoholic Beverages.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.